We recently published a list of the 11 Cheap NYSE Stocks to Invest in According to Hedge Funds. In this article, we are going ...

Amid fears of broad-brush pharmaceutical tariffs, Jim Cramer defended Johnson & Johnson (NYSE:JNJ) as an unjustified casualty ...

Shares in Swiss drugmaker Novartis (NVS) were looking perkier today as it set out plans to invest $23 billion in U.S. manufacturing to beat the ...

On the positive side, continued growth in sales of key drugs like Darzalex, along with newer products such as Erleada and ...

Johnson & Johnson (JNJ) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

We recently published a list of Jim Cramer Says Tariff Pain Isn’t Over Yet And Reviews These 9 Stocks. In this article, we ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

US President Donald Trump’s sudden, shocking 90-day pause on his so-called “reciprocal” tariffs (they were not reciprocal) ...

The pharmaceutical and healthcare sectors were previously viewed as a relative safe haven from the tariff-induced market turmoil. The Health Care Select Sector SPDR exchange-traded fund XLV fell 7.8% ...

Shares in major U.S. and European pharmaceutical companies fell sharply Wednesday, underperforming a broader market downturn, after U.S. President Donald Trump said the country would soon impose “a ...

Large-cap pharmaceutical stocks like these may now be positioned to outperform as the impact of tariffs begins to take hold.

Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients ...